세계의 신경통 치료 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료별, 적응증별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Global Neuralgia Treatment Market was valued at USD 1.21 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.84% through 2030. The Global Neuralgia Treatment Market in 2023 is characterized by significant growth and advancements in the diagnosis and management of neuralgia-related conditions.The global neuralgia treatment market is driven by factors such as the rising prevalence of neurological disorders, increasing geriatric population, advancements in drug development, growing awareness about pain management, enhanced healthcare access, and the rising demand for effective treatments for chronic pain conditions like trigeminal neuralgia and postherpetic neuralgia. For instance, in June 2024, the Australian Government committed USD 19.6 million from the Medical Research Future Fund to improve primary healthcare, emphasizing chronic pain and multidisciplinary care. USD 8.8 million will support chronic pain initiatives, focusing on rural communities and adapting programs to reduce disability, enhancing healthcare access and outcomes.

Key Market Drivers

Rising Prevalence of Neuralgia-Related Conditions

Neuralgia, a condition characterized by excruciating pain along nerve pathways, affects millions of individuals worldwide, significantly impacting their quality of life. While neuralgia encompasses various forms, including trigeminal neuralgia, postherpetic neuralgia, and diabetic neuropathy, one common trend is the rising prevalence of neuralgia-related conditions. This growing prevalence represents both a significant challenge and an opportunity for the healthcare industry. According to a 2024 Multiple Sclerosis (MS) Society study, over 150,000 people in the UK are living with multiple sclerosis (MS), with the increase attributed to improved diagnoses and longer life expectancies rather than a higher risk. The regional prevalence is: around 123,000 in England (1 in 450), 6,100 in Wales (1 in 500), 5,300 in Northern Ireland (1 in 350), and 17,400 in Scotland (1 in 300). Annually, more than 7,100 new cases are diagnosed, which averages to about 135 weekly.

Key Market Challenges

Underdiagnosis and Misdiagnosis

A major challenge is the underdiagnosis and misdiagnosis of neuralgia-related conditions. Many individuals endure their symptoms without seeking medical attention, often because they are unaware of their condition or its severity. Misdiagnosis can lead to inappropriate treatments and delays in receiving proper care.

Key Market Trends

Advanced Diagnostic Tools

Early and accurate diagnosis is crucial for effective neuralgia treatment. The development of more sophisticated diagnostic tools, such as high-resolution imaging, nerve conduction studies, and genetic testing, will enable healthcare professionals to identify neuralgia-related conditions with greater precision. Timely diagnosis will lead to more targeted treatments.

Key Market Players

• GSK PLC
• Pfizer Inc
• Novartis AG
• Biogen Inc
• Cadila Pharmaceuticals Ltd
• Lundbeck Pharmaceuticals Ltd
• Zydus Group (Cadila Healthcare Limited)
• Eli Lily and Company
• Allergan Inc.
• Baxter International Inc.

Report Scope:

In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuralgia Treatment Market, By Treatment:

• Drug-Based
• Surgery

Neuralgia Treatment Market, By Indication:

• Diabetic Neuropathy
• Intercostal Neuralgia
• Occipital Neuralgia
• Peripheral Neuralgia
• Postherpetic Neuralgia
• Trigeminal Neuralgia

Neuralgia Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Neuralgia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market.

Available Customizations:

Global Neuralgia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuralgia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Drug-Based, Surgery)
  • 5.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Treatment
  • 5.3.2. By Indication
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Neuralgia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Drug-Based, Surgery)
  • 6.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neuralgia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Neuralgia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Neuralgia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Neuralgia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment (Drug-Based, Surgery)
  • 7.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neuralgia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Neuralgia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France Neuralgia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Neuralgia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Neuralgia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Neuralgia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment (Drug-Based, Surgery)
  • 8.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Neuralgia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan Neuralgia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India Neuralgia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia Neuralgia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea Neuralgia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Distribution Channel

9. South America Neuralgia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment (Drug-Based, Surgery)
  • 9.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neuralgia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Neuralgia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Neuralgia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Neuralgia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment (Drug-Based, Surgery)
  • 10.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neuralgia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Neuralgia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Neuralgia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait Neuralgia Treatment Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Treatment
      • 10.3.4.2.2. By Indication
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. GSK PLC
• 14.2. Pfizer Inc
• 14.3. Novartis AG
• 14.4. Biogen Inc
• 14.5. Cadila Pharmaceuticals Ltd
• 14.6. Lundbeck Pharmaceuticals Ltd
• 14.7. Zydus Group (Cadila Healthcare Limited)
• 14.8. Eli Lily and Company
• 14.9. Allergan Inc.
• 14.10. Baxter International Inc.

15. Strategic Recommendations

16. About Us & Disclaimer